Table 5.
Response to lestaurtinib (N = 46)
| Best overall responses | |
| PR | 2/46 |
| Mixed | 3/46 |
| Stable disease | 20/46 |
| Progressive disease | 21/46 |
| Number of treatment courses prior to PD | |
| 4–10 months | 11a/46 |
| 11–16 months | 3b/46 |
| ≥17 months | 3/46 |
| Dose levels of response/SD > 5 months | |
| Dose level 1–3 | 0/9 (total subjects at dose levels 1–3) |
| Dose level 4–5c | 2/22 (2 SD) |
| Dose level 5a–8d | 8/16 (2 PR, 2 Mixed, 4 SD) |
Complete response (CR), Partial response (PR), Stable disease (SD)
a
One of 11 patients stopped therapy after 5 cycles due to toxicity
b
One of 3 patients stopped therapy after 13 cycles due to toxicity
c
Cohorts expanded, dose de-escalated then re-escalated for toxicity monitoring
d
Modified dose escalation (level 5–5a increased by 15%)